Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Predicting Benefit From Evolocumab Therapy in Patients With Atherosclerotic Disease Using a Genetic Risk Score: Results From the FOURIER Trial.

Circulation - 25 Feb 2020

Marston Nicholas A, Kamanu Frederick K, Nordio Francesco, Gurmu Yared, Roselli Carolina, Sever Peter S, Pedersen Terje R, Keech Anthony C, Wang Huei, Lira Pineda Armando, Giugliano Robert P, Lubitz Steven A, Ellinor Patrick T, Sabatine Marc S, Ruff Christian T

Abstract excerpt

BACKGROUND: The ability of a genetic risk score to predict risk in established cardiovascular disease and identify individuals who derive greater benefit from PCSK9 (proprotein convertase subtilisin/kexin type 9) inhibition has not been established. METHODS: We studied 14 298 patients with atherosclerotic cardiovascular disease from the FOURIER trial (Further Cardiovascular Outcomes Researh With PCSK9 Inhibition...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Antibodies, Monoclonal, Humanized
Share to Anticholesteremic Agents

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Atherosclerosis

Share to Cardiovascular Diseases

Share to Cholesterol, LDL

Share to Double-Blind Method

Share to Proportional Hazards Models

Share to Proprotein Convertase 9

Source

Open in PubMed Open full text

Identifiers

PMID: 31707849
DOI: 10.1161/CIRCULATIONAHA.119.043805
PMCID: PMC8058781

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Predicting Benefit From Evolocumab Therapy in Patients With Atherosclerotic Disease Using a Genetic Risk Score: Results From the FOURIER Trial.PMID 31707849Read ↗

Genetic Risk Prediction for Primary and Secondary Prevention of Atherosclerotic Cardiovascular Disease: an Update.Semantic proximity Read ↗

Genetic risk scores used in cardiovascular disease prediction models: a systematic review.Semantic proximity Read ↗

Genetic Regulation of PCSK9 (Proprotein Convertase Subtilisin/Kexin Type 9) Plasma Levels and Its Impact on Atherosclerotic Vascular Disease Phenotypes.Semantic proximity Read ↗

PCSK9 loss of function is protective against extra-coronary atherosclerotic cardiovascular disease in a large multi-ethnic cohort.Semantic proximity Read ↗

Genomic and Precision Medicine Approaches in Atherosclerotic Cardiovascular Disease: From Risk Prediction to Therapy—A ReviewSemantic proximity Read ↗

Prediction of Coronary Artery Disease and Major Adverse Cardiovascular Events Using Clinical and Genetic Risk Scores for Cardiovascular Risk Factors.Semantic proximity Read ↗

Type 2 diabetes genetic risk and incident diabetes across diabetes risk enhancers.Semantic proximity Read ↗

PCSK9 genetic variants and risk of vascular and non-vascular diseases in Chinese and UK populations.Semantic proximity Read ↗

Marginal role for 53 common genetic variants in cardiovascular disease prediction.Semantic proximity Read ↗

Variation in PCSK9 and HMGCR and Risk of Cardiovascular Disease and Diabetes.Semantic proximity Read ↗

Endothelial cell-related genetic variants identify LDL cholesterol-sensitive individuals who derive greater benefit from aggressive lipid lowering.Semantic proximity Read ↗

Incremental value of a genetic risk score for the prediction of new vascular events in patients with clinically manifest vascular disease.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.